Demegen, Inc. and Dow Pharmaceutical Sciences have entered into a collaborative agreement to develop certain Demegen peptides into prescription pharmaceutical products.
Under the terms of this agreement, Dow Pharmaceutical Sciences will be responsible for selecting suitable Demegen compounds for several topical disease indications; developing them and filing FDA applications; along with providing certain other services for Demegen.
Additional terms were not disclosed.
Dow Pharmaceutical Sciences specializes in topical formulations.
Full- scope in nature, they provide full product development support including regulatory, nonclinical and clinical trial management needed for FDA approvals.
Demegen develops novel and natural peptides for the treatment of bacterial and fungal infections.
Other products to be developed include treatments for cystic fibrosis infections, for which there is an Orphan Drug designation, oral candidiasis, and sexually transmitted infections.